Biocon Limited’s Board of Directors met on May 07, 2026, to approve the audited financial results for the quarter and financial year ended March 31, 2026. The company reported a consolidated revenue of ₹4,569 Crore for Q4FY26, representing a 27% increase from the previous quarter’s ₹3,597 Crore and a 16% growth over the ₹3,929 Crore recorded in the same quarter last year. Net profit (before exceptional items) stood at ₹179 Crore, showing a significant 44% jump from the previous quarter’s ₹124 Crore and a 74% increase from ₹103 Crore in the corresponding quarter of the previous year.

*Net Profit figures are before exceptional items as per company highlights.

Biocon Limited is an innovation-led global biopharmaceuticals company that operates through three key segments: Biosimilars, Generics, and Research Services (Syngene). Founded by Kiran Mazumdar-Shaw, the company has evolved into a global leader, particularly in the biosimilars market, where it ranks among the top five players worldwide. The company recently completed the full integration of its biosimilars and generics businesses, a strategic move intended to create a unified global biopharmaceutical enterprise. Biocon maintains a strong focus on high-growth areas such as insulins, oncology, and immunology, while also expanding its presence in emerging markets through strategic tender wins and regulatory approvals.